MedDataX Logo

Alemtuzumab and Combination Chemotherapy Followed By Donor Lymphocytes in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer

NCT ID: NCT00104975

Last Updated: 2016-12-15

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

20 participants

Study Classification

INTERVENTIONAL

Study Start Date

2005-02-28

Study Completion Date

2008-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

RATIONALE: Giving low doses of chemotherapy before a donor peripheral blood stem cell transplant helps stop the growth of cancer cells. It also stops the patient's immune system from rejecting the donor's stem cells. The donated stem cells may replace the patient's immune system and help destroy any remaining cancer cells (graft-versus-tumor effect). Giving an infusion of the donor's T cells that have been treated in the laboratory after the transplant may help increase this effect. Sometimes the transplanted cells from a donor can also make an immune response against the body's normal cells. Giving tacrolimus before and after transplant may stop this from happening.

PURPOSE: This phase I trial is studying the side effects and best dose of donor lymphocytes when given after alemtuzumab and combination chemotherapy in treating patients who are undergoing donor stem cell transplant for hematologic cancer.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

OBJECTIVES:

* Determine the feasibility and efficacy of a reduced-intensity conditioning regimen comprising alemtuzumab, fludarabine, melphalan, and thiotepa followed by allogeneic peripheral blood stem cell transplantation (PBSCT) in patients with hematologic malignancies.
* Determine the toxicity of this regimen in these patients.
* Determine the safety of LMB-2 immunotoxin-treated, selectively-depleted donor T cells, administered after allogeneic PBSCT, in these patients.

OUTLINE: This is a dose-escalation study of LMB-2 immunotoxin-treated, selectively-depleted donor T cells.

* T cell preparation: Patients and donors undergo apheresis to obtain peripheral blood mononuclear cells (PBMCs), which are expanded in culture. Patients' PBMCs are irradiated and mixed with donor PBMCs. LMB-2 immunotoxin is added to the PBMCs in order to selectively deplete T cells from the donor PBMCs.
* Conditioning: Patients receive alemtuzumab IV over 2 hours on days -9 to -5, fludarabine IV over 30 minutes on days -8 to -5, melphalan IV over 15-20 minutes on day -4, and thiotepa IV on days -3 to -2.
* Immunosuppression: Patients receive tacrolimus IV continuously on days -10 to 1.
* Allogeneic peripheral blood stem cell (PBSC) transplantation: Patients undergo allogeneic PBSC transplantation on day 0.
* LMB-2 immunotoxin-treated, selectively-depleted donor T cells: Patients receive LMB-2 immunotoxin-treated, selectively-depleted donor T cells IV over 30-60 minutes on approximately day 28.

Cohorts of 3-6 patients receive escalating dose of LMB-2 immunotoxin-treated, selectively-depleted donor T cells until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 6 patients experience dose-limiting-toxicity.

After completion of study treatment, patients are followed weekly for 100 days post-transplantation and then periodically for survival.

PROJECTED ACCRUAL: A total of 15-20 patients will be accrued for this study.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Chronic Myeloproliferative Disorders Leukemia Lymphoma Myelodysplastic Syndromes Myelodysplastic/Myeloproliferative Neoplasms

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

accelerated phase chronic myelogenous leukemia recurrent adult Burkitt lymphoma stage IV adult Burkitt lymphoma recurrent adult lymphoblastic lymphoma stage IV adult lymphoblastic lymphoma recurrent adult immunoblastic large cell lymphoma stage IV adult immunoblastic large cell lymphoma refractory anemia with excess blasts in transformation refractory anemia with excess blasts secondary myelodysplastic syndromes chronic myelomonocytic leukemia blastic phase chronic myelogenous leukemia chronic eosinophilic leukemia primary myelofibrosis chronic neutrophilic leukemia essential thrombocythemia polycythemia vera adult acute myeloid leukemia in remission adult acute myeloid leukemia with 11q23 (MLL) abnormalities adult acute myeloid leukemia with inv(16)(p13;q22) adult acute myeloid leukemia with t(15;17)(q22;q12) adult acute myeloid leukemia with t(16;16)(p13;q22) adult acute myeloid leukemia with t(8;21)(q22;q22) recurrent adult acute myeloid leukemia refractory chronic lymphocytic leukemia stage III chronic lymphocytic leukemia stage IV chronic lymphocytic leukemia stage III adult Burkitt lymphoma stage III adult immunoblastic large cell lymphoma stage III adult lymphoblastic lymphoma myelodysplastic/myeloproliferative neoplasm, unclassifiable de novo myelodysplastic syndromes previously treated myelodysplastic syndromes atypical chronic myeloid leukemia, BCR-ABL1 negative

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Primary Study Purpose

TREATMENT

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

alemtuzumab

Intervention Type BIOLOGICAL

therapeutic allogeneic lymphocytes

Intervention Type BIOLOGICAL

fludarabine phosphate

Intervention Type DRUG

melphalan

Intervention Type DRUG

tacrolimus

Intervention Type DRUG

thiotepa

Intervention Type DRUG

peripheral blood stem cell transplantation

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

DISEASE CHARACTERISTICS:

* Diagnosis of 1 of the following hematologic malignancies:

* Chronic myelogenous leukemia

* Accelerated phase or blast phase
* Acute myeloid leukemia, meeting any of the following criteria:

* In second or subsequent remission
* In primary induction failure
* In partial remission
* In resistant relapse
* Chronic lymphocytic leukemia

* In Richter's transformation
* High-grade non-Hodgkin's lymphoma

* Refractory to standard treatment
* Myeloproliferative disorders

* Undergoing transformation to terminal stages
* Myelodysplastic syndromes (MDS), including any of the following:

* Refractory anemia with excess blasts
* Transformation to acute leukemia
* MDS secondary to chemotherapy
* Partially-matched related family donor available

* One HLA haplotype match
* No HLA-matched (10/10 or 9/10) sibling donor or unrelated donor available NOTE: A new classification scheme for adult non-Hodgkin's lymphoma has been adopted by PDQ. The terminology of "indolent" or "aggressive" lymphoma will replace the former terminology of "low", "intermediate", or "high" grade lymphoma. However, this protocol uses the former terminology.

PATIENT CHARACTERISTICS:

Age

* 18 to 55

Performance status

* ECOG 0-1

Life expectancy

* Not specified

Hematopoietic

* Not specified

Hepatic

* SGOT and SGPT \< 3 times upper limit of normal (ULN)
* No active or persistent viral hepatitis

Renal

* Creatinine \< 2.0 mg/dL\* OR
* Creatinine clearance \> 60 mL/min\* NOTE: \*Unless due to malignancy

Cardiovascular

* LVEF ≥ 45%

Pulmonary

* DLCO ≥ 60% of predicted\* (corrected for hemoglobin) NOTE: \*Unless patient is given clearance by a pulmonary consultation

Other

* Not pregnant or nursing
* Negative pregnancy test
* Fertile patients must use effective contraception during and for up to 2 years after completion of study treatment
* HIV negative
* Human T cell lymphotrophic virus type 1 negative
* No serious co-morbid medical condition
* No other medical condition that would preclude study compliance

PRIOR CONCURRENT THERAPY:

Biologic therapy

* Not specified

Chemotherapy

* Not specified

Endocrine therapy

* Not specified

Radiotherapy

* Not specified

Surgery

* Not specified
Minimum Eligible Age

18 Years

Maximum Eligible Age

55 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

National Cancer Institute (NCI)

NIH

Sponsor Role collaborator

Yale University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Erkut Bahceci, MD

Role: STUDY_CHAIR

Yale University

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Yale Cancer Center

New Haven, Connecticut, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

YALE-25971

Identifier Type: -

Identifier Source: secondary_id

NCI-6765

Identifier Type: -

Identifier Source: secondary_id

CDR0000413698

Identifier Type: -

Identifier Source: org_study_id